Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.
Immunotherapy may prolong survival compared with standard chemotherapy.
New research suggests how to better predict which patients will respond to immunotherapy.
Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.
Predicting who is likely or unlikely to respond to checkpoint inhibitors remains a focus for researchers.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
The new documentary follows the pioneering researcher who work helped created checkpoint inhibitor immunotherapy.
Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.
The findings could help identify patients who might benefit from combination therapy with a checkpoint blocker and another inhibitor.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
Yung S. Lie, PhD, is the president and CEO of the Damon Runyon Cancer Research Foundation.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
After finding a protein that smoking affects to drive head and neck cancer, investigators hope manipulating it will prove beneficial.
Betting on basic science is leading to breakthroughs in immune checkpoint inhibitors, CAR-T, targeted therapies, cancer vaccines and more.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.